Texas Allergy Experts
texasallergyexperts.com

SEVERE ASTHMA

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. Lorem ipsum dolor sit. amet.consetetur sadipscing elitr, sed diam nonumy eirmod tempor. invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. Lorem ipsum

Sed Diam Volputua

Lorem Ipsum

L

Profile of lebrikizumab and its potential in the treatment of asthma Full Text 
Journal of Asthma and Allergy, 08/14/2015  Review Article

Maselli DJ, et al. – Interleukin (IL)–13 has been associated with multiple inflammatory features of asthma. It affects multiple cellular lines in asthma and is a key mediator in airway hyperreactivity and remodeling. Other therapies that target IL–13 and the receptor of IL–4/IL–13 have been studied, but future studies are needed to determine their role in the treatment of asthma.

  • Periostin, an extracellular protein, has been used as a surrogate marker of IL–13 activity and has been linked to airway remodeling by inducing subepithelial fibrosis.
  • Lebrikizumab is a humanized monoclonal antibody that targets IL–13.
  • Studies have demonstrated promising results with lebrikizumab therapy in asthma with regard to pulmonary function and exacerbation rates, especially on those patients with surrogate markers of T helper cell type 2–driven inflammation (ie, elevated immunoglobulin E levels, eosinophil counts, periostin levels).
  • Lebrikizumab appears to be a safe therapy, but there are ongoing studies evaluating its efficacy and safety profile.

 nonummy.

Aenaeaen ampirius

Lorem Ipsum

Aenean amturpis. Maecenas hend, massa laoreet iaculi pede mnisl

  • Aliquyam erat, sed diam
  • Vidunt ut labore et dolore
  • Consetetur sadipscing elitr

Aenean amturpis. Maecenas hend, massa laoreet iaculi pede mnisl

Adepi ET Iacualit

Lorem Ipsum

Lorem ipsum dolor sit amet, consectetuer adipi scing. Mauris urna urna, varius et

Aenean amturpis. Maecenas hend, massa laoreet iaculi

Pede Proin nunc. Donec masa Nulla pulvinar, nisl